Recent Updates
Recently added Catalysts
ACOG Positive Sentiment

Alpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress

Tuesday, October 6, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Alpha Cognition Inc. announced the presentation of new clinical and real-world data on ZUNVEYL and acetylcholinesterase inhibitors at the ASCP Annual Meeting. This event is scheduled for October 29 to November 1, 2026. The focus on neurodegenerative diseases underscores the company's commitment to advancing treatment options.

Market Sentiment Analysis

POSITIVE FACTORS

  • Alpha Cognition is presenting new clinical data on ZUNVEYL.
  • The presentation will occur at a significant industry event.
  • Focus on therapies for neurodegenerative diseases highlights innovation.

Full Press Release Details

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that new clinical and real-world data on ZUNVEYL and acetylcholinesterase inhibitors will be presented at the American Society of Consultant Pharmacists (ASCP) Annual Meeting, taking place October 29-November 1, 2026 and Neuroscience Education I

Frequently Asked Questions

What is ZUNVEYL?

ZUNVEYL is a therapy developed by Alpha Cognition for neurodegenerative diseases.

When will the ASCP Annual Meeting take place?

The ASCP Annual Meeting is scheduled for October 29 to November 1, 2026.

What type of data will be presented?

New clinical and real-world data on ZUNVEYL and acetylcholinesterase inhibitors will be presented.

Who is Alpha Cognition?

Alpha Cognition Inc. is a biopharmaceutical company focused on therapies for neurodegenerative diseases.

ShareAdd on Google
Tags: ACOG Alpha Cognition ZUNVEYL ASCP Annual Meeting neurodegenerative diseases clinical data
Last updated: Oct 6, 2026

Biotech snapshot

Cash runway
$41M liquidity · $2M/mo burn
~16 mo
Low dilution risk